Evelo Biosciences, Inc.
US ˙ OTCPK ˙ US2997342025

Introduction

This page provides a comprehensive analysis of the known insider trading history of Nancy A Simonian. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Nancy A Simonian has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:SYRS / Syros Pharmaceuticals, Inc. Director 4,000
US:SGEN / Seagen Inc Director 0
US:EVLO / Evelo Biosciences, Inc. Director 15,690
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Nancy A Simonian. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases EVLO / Evelo Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EVLO / Evelo Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EVLO / Evelo Biosciences, Inc. Insider Trades
Insider Sales EVLO / Evelo Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EVLO / Evelo Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EVLO / Evelo Biosciences, Inc. Insider Trades
Insider Purchases SYRS / Syros Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EVLO / Evelo Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Sales SYRS / Syros Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EVLO / Evelo Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-12-02 SYRS Simonian Nancy A 37,070 0.2702 37,070 0.2702 10,016 101 0.0765 -7,180 -71.69
2024-11-25 SYRS Simonian Nancy A 134,713 0.2653 134,713 0.2653 35,739

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Nancy A Simonian as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-12-04 2024-12-02 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
S - Sale -37,070 4,000 -90.26 0.27 -10,016 1,081
2024-11-27 2024-11-25 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
S - Sale -134,713 41,070 -76.64 0.27 -35,739 10,896
2024-11-04 2024-10-31 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 40,125 175,783 29.58
2024-06-07 2024-06-05 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 4,000 135,658 3.04
2024-04-02 2024-04-01 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
F - Taxes -14,052 131,658 -9.64 5.12 -71,946 674,089
2024-04-02 2024-03-31 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 39,566 145,710 37.28
2024-04-02 2024-03-31 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,000 106,144 5.99
2023-12-15 2023-12-14 4 SGEN Seagen Inc.
Common Stock
D - Sale to Issuer -62,753 0 -100.00 229.00 -14,370,437
2023-11-02 2023-11-01 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
F - Taxes -13,401 100,144 -11.80 2.22 -29,750 222,320
2023-11-02 2023-10-31 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 40,125 113,545 54.65
2023-06-02 2023-05-31 4 SGEN Seagen Inc.
Common Stock
A - Award 2,044 64,797 3.26
2023-04-04 2023-04-03 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
F - Taxes -1,852 73,420 -2.46 2.58 -4,778 189,424
2023-04-04 2023-03-31 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,000 75,272 8.66
2022-12-14 2022-12-12 4 SGEN Seagen Inc.
Common Stock
M - Exercise 8,750 62,753 16.20 36.70 321,125 2,303,035
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3,676 3,676
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Common Stock
A - Award 1,503 54,003 2.86
2022-04-04 2022-04-01 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
F - Taxes -58,883 692,723 -7.83 1.12 -65,949 775,850
2022-03-04 2022-03-02 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
M - Exercise -25,000 0 -100.00
2022-03-04 2022-03-02 4 SGEN Seagen Inc.
Common Stock
M - Exercise 25,000 52,500 90.91 20.04 501,000 1,052,100
2022-02-17 2022-02-15 4 SYRS Syros Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 400,000 400,000
2022-02-17 2022-02-15 4 SYRS Syros Pharmaceuticals, Inc.
Restricted Stock Units
A - Award 240,000 240,000
2022-02-17 2022-02-15 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 375,000 375,000
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3,462 3,462
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Common Stock
A - Award 1,402 27,500 5.37
2021-02-19 2021-02-17 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 304,000 304,000
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -4,988 280,012 -1.75
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -14,168 79,165 -15.18
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -10,761 21,524 -33.33
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,988 563,606 0.89 10.09 50,329 5,686,785
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 14,168 558,618 2.60 8.51 120,570 4,753,839
2020-12-21 2020-12-18 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 10,761 544,450 2.02 3.04 32,713 1,655,128
2020-06-18 2020-06-17 4 EVLO Evelo Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 15,690 15,690
2020-05-19 2020-05-15 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 3,171 3,171
2020-05-19 2020-05-15 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 1,335 26,098 5.39
2020-02-14 2020-02-13 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 294,000 294,000
2019-12-23 2019-12-23 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -8,210 1,018,123 -0.80
2019-12-23 2019-12-23 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -10,762 1,026,333 -1.04
2019-12-23 2019-12-23 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise -33,429 1,037,095 -3.12
2019-12-23 2019-12-23 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 52,401 533,689 10.89 3.04 159,299 1,622,415
2019-06-13 2019-06-12 4 EVLO Evelo Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 15,690 15,690
2019-05-22 2019-05-20 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 7,038 7,038
2019-05-22 2019-05-20 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 2,963 24,763 13.59
2019-02-14 2019-02-12 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 285,000 285,000
2019-02-14 2019-02-12 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
A - Award 188,000 669,288 39.06
2018-12-03 2018-11-29 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise 12,084 785,523 1.56
2018-12-03 2018-11-29 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise 75,050 797,607 10.39
2018-12-03 2018-11-29 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
M - Exercise 23,454 872,657 2.76
2018-12-03 2018-11-29 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,084 481,288 2.58 3.04 36,735 1,463,116
2018-12-03 2018-11-29 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
M - Exercise 98,504 469,204 26.57 1.01 99,489 473,896
2018-05-22 2018-05-18 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9,260 9,260
2018-05-22 2018-05-18 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,700 21,800 20.44
2018-05-10 2018-05-08 4 EVLO Evelo Biosciences, Inc.
Stock Option
A - Award 31,380 31,380
2018-02-21 2018-02-16 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 285,000 285,000
2017-05-23 2017-05-19 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9,260 9,260
2017-05-23 2017-05-19 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,700 18,100 25.69
2017-02-13 2017-02-10 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 175,000 175,000
2016-09-19 2016-09-16 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 75,000 75,000
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Series A-2 Preferred Stock
C - Conversion -250,000 0 -100.00
2016-07-06 2016-07-06 4 SYRS Syros Pharmaceuticals, Inc.
Common Stock
C - Conversion 66,666 370,702 21.93
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
768,072
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
544,036
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
544,036
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
768,072
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
544,036
2016-06-29 3 SYRS Syros Pharmaceuticals, Inc.
Common Stock
544,036
2016-05-24 2016-05-20 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9,260 9,260
2016-05-24 2016-05-20 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,700 14,400 34.58
2015-05-19 2015-05-15 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 9,260 9,260
2015-05-19 2015-05-15 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,700 10,700 52.86
2014-05-20 2014-05-16 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 8,750 8,750 34.25 299,688 299,688
2014-05-20 2014-05-16 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,500 7,000 100.00
2013-05-21 2013-05-17 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 8,750 8,750 36.70 321,125 321,125
2013-05-21 2013-05-17 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 3,500 3,500
2012-03-21 2012-03-19 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 25,000 25,000 20.04 501,000 501,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)